PPT-Telaprevir in Treatment

Author : liane-varnes | Published Date : 2017-05-05

Naïve GT1 ILLUMINATE Study 111 Phase 3 Treatment Naïve Sherman KE et al N Engl J Med 2011365101424 Source Sherman KE et al N Engl J Med 2011365101424 Telaprevir

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Telaprevir in Treatment" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Telaprevir in Treatment: Transcript

Naïve GT1 ILLUMINATE Study 111 Phase 3 Treatment Naïve Sherman KE et al N Engl J Med 2011365101424 Source Sherman KE et al N Engl J Med 2011365101424 Telaprevir for TreatmentNaïve HCV Genotype . ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR + SMV placebo + PEG-IFN + RBV. Randomisation*. 1 : 1. Double-blind. ≥ 18 years. HCV genotype 1. HCV RNA ≥ 10,000 IU. /ml. Null or partial responders to . Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. Mark S. Sulkowski, MD. Medical Director, Viral Hepatitis Center. Divisions of Infectious Diseases and Gastroenterology/Hepatology. Johns Hopkins University School of Medicine. Baltimore, Maryland. Treatment-Naive Data . Naïve GT-1. ADVANCE (Study 108). Phase . 3. Treatment. . Naïve. Jacobson IM, et. al. N . Engl. J Med. 2011;364:2405-16. .. Source: Jacobson . IM, et. al. . N . Engl. J Med. 2011;364:2405-16.. Telaprevir for Treatment-Naïve HCV Genotype . BID versus q8 in Treatment Naïve GT-1. OPTIMIZE (. Study . C211). Phase . 3. Treatment. . Naïve. Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. ahead of print]. Source: . Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Regina . Ubaldi. -Rosen, CRNP. ELLAH NOTA, CRNP. GUIDANCE FOR HCV/HIV Co-infection Programs. AIDS CARE GROUP. Is a . non-profit organization that provides medical care, dental care, and social services to uninsured and underinsured minority residents of Chester, Delaware County, . Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. OPTIMIZE (. Study . C211). Phase . 3. Treatment. . Naïve. Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. ahead of print]. Source: . Buti. M, et al. Gastroenterology. 2013 Dec 4. [. Epub. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. really necessary?. Peter . Ferenci. Medical University of Vienna. Treatment . of. . chronic. non-. A,non. -B . hepatitis. . with. . recombinant. human . alpha. . interferon. . A . preliminary. in Hepatitis C . Paris . Februari. 2012. Ola . Weiland. Karolinska Institutet. Stockholm, Sweden. New major adverse events with PIs. . Exanthema for TVR. . Prolonged anemia with BOC. Telaprevir. Illuminate study.

Download Document

Here is the link to download the presentation.
"Telaprevir in Treatment"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.